Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (GB:0A4W)
LSE:0A4W
ACADIA Pharmaceuticals (0A4W) Stock Price & Analysis
0 Followers
0A4W Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.27 - $27.71
Previous Close$18.38
Volume0.00
Average Volume (3M)1.15K
Market Cap
$3.02B
Enterprise Value$2.66B
Total Cash (Recent Filing)$416.82M
Total Debt (Recent Filing)$62.00M
Price to Earnings (P/E)N/A
Beta0.06
Next Earnings
May 03, 2023EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding162,230,184
10 Day Avg. Volume158
30 Day Avg. Volume1,147
Standard Deviation0.13
R-Squared0.15
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)7.39
Price to Sales (P/S)14.69
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-25.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.15
Enterprise Value/Gross Profit5.25
Enterprise Value/Ebitda-12.02
Forecast
1Y Price Target
$22.82Price Target Upside24.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
ACADIA Pharmaceuticals News
0A4W FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $12.27 and its highest was $27.70 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
Currently, no data Available
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is May 03, 2023 which is in 36 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Feb 27, 2023. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.247 by -$0.013.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is -$0.22.
How many shares outstanding does ACADIA Pharmaceuticals have?
Currently, no data Available
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.247. Following the earnings report the stock price went up 12.965%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Among the largest hedge funds holding ACADIA Pharmaceuticals’s share is Baker Bros Advisors LP. It holds ACADIA Pharmaceuticals’s shares valued at 667M.
---
ACADIA Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.82 (24.14% Upside)
$22.82 (24.14% Upside)
Blogger Sentiment
Bullish
GB:0A4W Sentiment 66%
Sector Average 68%
Sector Average 68%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.82%
12-Months-Change
Fundamentals
Return on Equity
-45.89%
Trailing 12-Months
Asset Growth
-16.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
---
PTC Therapeutics
―
Blueprint Medicines
―
IVERIC bio
―
Ultragenyx Pharmaceutical
―
Insmed
―
---